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Adiponectin and cancer: a systematic review
I Kelesidis1,2, T Kelesidis1,2 and CS Mantzoros*,1
1Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Boston, MA, USA
Recent studies have demonstrated that obesity is a significant risk factor for the development of several malignancies, but the
mechanisms underlying this relationship remain to be fully elucidated. Adiponectin, an adipocyte secreted endogenous insulin
sensitizer, appears to play an important role not only in glucose and lipid metabolism but also in the development and progression of
several obesity-related malignancies. In this review, we present recent findings on the association of adiponectin with several
malignancies as well as recent data on underlying molecular mechanisms that provide novel insights into the association between
obesity and cancer risk. We also identify important research questions that remain unanswered.
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Obese subjects have not only increased risk of developing cancer
(Wolk et al, 2001), but their mortality is also increased with
increasing BMI, especially when the BMI is 440 kg m2. More
specifically, obesity has been identified as a risk factor for several
cancers including endometrial cancer and breast cancer (especially
after menopause), colon and rectal, oesophageal, kidney, pancrea-
tic, biliary, ovarian, cervical and liver cancer (Wolk et al, 2001;
Larsson and Wolk, 2006). Inconsistent data have been reported for
prostate cancer (Wolk et al, 2001; Larsson and Wolk, 2006) but
most studies have suggested a modest increase in risk of advanced
prostate cancer with increasing body mass. Although adenocarci-
noma of the gastric cardia is obesity related, data are limited and
inconsistent for noncardia cancers of the stomach as is on the
relationship between haematopoietic malignancies and BMI (Wolk
et al, 2001; Larsson and Wolk, 2006).
Consequently, there is evidence in humans for a cancer-
preventive effect of avoidance of weight gain for cancers of colon,
breast (postmenopausal), endometrium, kidney and adenocarci-
noma of the esophagus (Wolk et al, 2001; Larsson and Wolk,
2006). The above epidemiologic associations and recommenda-
tions are consistent with animal studies showing that caloric
restriction dramatically decreases spontaneous and carcinogen-
induced tumour incidence, multiplicity and size (Wolk et al, 2001;
Larsson and Wolk, 2006).
ENDOCRINE SYSTEMS/ADIPONECTIN AS A LINK
BETWEEN OBESITY AND CANCER
Understanding the associations between overweight, obesity and a
wide variety of cancers, as well as the biological mechanisms
contributing to these associations, remains an evolving and
currently very active area of research. Steroid hormones, insulin,
insulin-like growth factor systems and adipokines are endocrine
systems that have been associated with carcinogenesis (Wolk et al,
2001). We focus herein on adiponectin; a recently identified
adipocyte secreted endogenous insulin sensitizer, circulating levels
of which have been associated with insulin resistance/insulinemia
and sex steroids.
Adiponectin: general information
Adiponectin is a recently identified adipocyte secreted hormone
expressed exclusively in adipocytes. Also called gelatin-binding
protein-28 (GBP28), AdipoQ, ACRP30 or apM1, adiponectin is
considered a link between obesity, insulin resistance and diabetes.
The human adiponectin gene (apM1) is located on chromosome
3q27 coding for a 244 amino-acid polypeptide (Chandran et al,
2003).
Adiponectin consists of three domains including a signal
peptide, a collagen-like motif and a globular domain. In addition,
adiponectin exists in the circulation in at least two forms, low
molecular weight (LMW) oligomers that is hexamers (two trimers)
and high molecular weight (HMW) oligomers consisting of four–
six trimers. Although the majority of intracellular adiponectin
consists of HMW oligomers, LMW oligomers are the predominant
form of adiponectin in the circulation (Pajvani et al, 2004). It has
been recently suggested that the HMW adiponectin complex is the
major source of the active form of this protein (Pajvani et al, 2004).
Adiponectin is abundant in human plasma, with concentrations
ranging from 3 to 30 mg ml1 and accounting for up to 0.05% of
total plasma protein (Chandran et al, 2003).
Determinants of adiponectin levels in the circulation
In contrast to most adipose-tissue-derived proteins, plasma
adiponectin levels are found to be lower in obese than in lean
subjects. Thus, a negative correlation between obesity, especially
central obesity, insulin resistance, type 2 diabetes (T2D) and
circulating adiponectin has been well established (Chandran et al,
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2003). Adiponectin concentrations increase with weight loss
(Chandran et al, 2003). Thus, plasma adiponectin levels are
reduced in (a) in obese and diabetic mice and humans (Trujillo
and Scherer, 2005) (b) cardiovascular disease (Trujillo and
Scherer, 2005), (c) hypertension and/or (d) metabolic syndrome
(Trujillo and Scherer, 2005). Testosterone decreases adiponectin
levels and adiponectin has recently been inversely associated with
oestrogen levels. Thus, although women have higher adiponectin
levels than men independently of body fat mass or fat distribution
(Cnop et al, 2003), postmenopausal women have significantly
higher adiponectin levels compared with premenopausal women
(Cnop et al, 2003). In addition, adiponectin gene expression is
reversibly downregulated by insulin and plasma adiponectin
concentration is inversely correlated with fasting plasma insulin
(Hotta et al, 2000). Recent studies (Qi et al, 2005) suggest that
dietary factors may modulate plasma adiponectin concentrations.
Caloric restriction and weight loss as well as diets with low
glycemic load increase adiponectin levels (Qi et al, 2005;
Mantzoros et al, unpublished observations).
Adiponectin receptors
Two adiponectin receptor forms (AdipoR1 and R2) have recently
been cloned (Yamauchi et al, 2003) and shown to have unique
distributions and affinities for the different forms of circulating
adiponectin. Specifically, AdipoR1 is a high-affinity receptor for
globular adiponectin, but also has a very low affinity for the full-
length molecule and is expressed ubiquitously. It is most abundant
in skeletal muscle, but is also present in endothelial cells and other
tissues (Goldstein and Scalia, 2004). AdipoR2 has intermediate
affinity for both forms of adiponectin and is predominantly
expressed in the liver (Goldstein and Scalia, 2004). AdipoR1 and
AdipoR2 appear to be integral membrane proteins; the N terminus
is internal, and the C terminus is external, which is opposite to
the topology of all other reported G protein-coupled receptors
(Yamauchi et al, 2003). AdipoR1 and AdipoR2 may form both
homo- and heteromultimers, and it is increasingly recognized that
adiponectin receptors mediate fatty-acid oxidation and glucose
uptake by adiponectin (Yamauchi et al, 2003). Finally, T-cadherin,
a cell-surface receptor located on endothelial and smooth muscle
cells, involved in calcium mediated cell–cell interactions and
signalling was also found to bind strongly HMW forms but not
trimeric/globular forms of adiponectin and it is thought to act as a
coreceptor (Hug et al, 2004). The histochemical localization of
T-cadherin is intriguing because it is similar to the localization
of adiponectin receptors (Hug et al, 2004). T-cadherin may
participate in signalling through its association with other
membrane proteins and incorporation into specific lipid domains
of the cell membrane and/or it may restrict proliferation of the
intima through its interactions with adiponectin (Hug et al, 2004).
The significance of similar interactions in the area of carcino-
genesis remains to be fully explored.
Adiponectin and risk of various types of cancer
Our group and others have recently reported that circulating
adiponectin levels in vivo are inversely associated with the risk of
malignancies associated with obesity and insulin resistance (Housa
et al, 2005), that is, endometrial cancer (Petridou et al, 2003; Dal
Maso et al, 2004), postmenopausal breast cancer (Mantzoros et al,
2004), leukaemia (Petridou et al, 2006) and colon cancer (Wei et al,
2005). Moreover, low adiponectin levels have been associated with
gastric cancer (Ishikawa et al, 2005) and prostate cancer (Goktas
et al, 2005).
Adiponectin and breast cancer Obesity has been shown to
increase rates of breast cancer in postmenopausal women
consistently by 3050% (Wolk et al, 2001). As insulin resistance
and obesity have been associated with development of breast
cancer, we hypothesized that decreased adiponectin levels might
underlie the association between breast cancer and obesity
(Mantzoros et al, 2004). Our initial observations based on a case
control study, were confirmed by subsequent studies showing that
lower-circulating adiponectin levels are associated with increased
risk of breast cancer (Miyoshi et al, 2003; Mantzoros et al, 2004;
Chen et al, 2005) independent of age, menopause status, hormone
receptor status, lymph nodes metastases, status of oestrogen
receptor, HER2/neu (Chen et al, 2005). Additionally, some but not
all studies have suggested that breast tumours arising in women
with low-serum adiponectin levels may have a more aggressive
phenotype (large size of tumour and high histological grade)
(Miyoshi et al, 2003; Mantzoros et al, 2004; Chen et al, 2005).
Adiponectin and endometrial cancer In women diagnosed with
endometrial cancer, obesity is more prevalent in premenopausal,
compared with postmenopausal women (Wolk et al, 2001). We
were the first to report that adiponectin is inversely related with
risk of endometrial cancer, especially among women younger than
65 years (Petridou et al, 2003). The inverse relation of adiponectin
with risk of endometrial cancer is independent of possible effects
of IGF-I, IGF-II, IGFBP-3, leptin, BMI and other known risk factors
of the disease, but the combination of high BMI and low
adiponectin levels led to a more than six-fold excess risk of
endometrial cancer (Miyoshi et al, 2003; Mantzoros et al, 2004;
Petridou et al, 2003).
Adiponectin and colon cancer We have also recently evaluated
the association between adiponectin and colorectal cancer in a
case–control study nested in the large prospective Health
Professionals Follow-up study and found that plasma adiponectin
levels were inversely associated with risk for colorectal cancer in
men (Wei et al, 2005). Individuals in the highest adiponectin
quintile had an approximately 60% reduced risk for colorectal
cancer compared to the lowest quintile, the association being
independent of body mass index, waist circumference, waist-to-hip
ratio and physical activity (Wei et al, 2005).
Adiponectin and gastric cancer Plasma adiponectin levels have
also been found to be lower in patients with gastric cancer,
especially in upper gastric cancers, compared to normal controls
and are inversely correlated with tumour size, depth of invasion
and tumour TNM stage, suggesting a potential role for adiponectin
in progression of gastric cancer (Ishikawa et al, 2005).
Adiponectin and prostate cancer A small case– control study
(Goktas et al, 2005) indicates that plasma adiponectin levels are
significantly lower in subjects with prostate cancer than in subjects
with benign prostatic hyperplasia or in normal healthy controls. In
addition, plasma adiponectin levels were negatively associated with
histological grade and disease stage (Goktas et al, 2005).
Adiponectin and leukaemia Adiponectin suppresses the growth
of myelomonocyte cells lines, and induces apoptosis in myelomo-
nocytic progenitor cells (leukaemia lines) in vitro (Yokota et al,
2000). We have recently shown that circulating adiponectin is
inversely associated with risk for acute myelogenous leukaemia
(AML) but not acute lymphoblastic leukaemia (ALL) in children
(Petridou et al, 2006).
Mechanisms that may link adiponectin with carcinogenesis
Indirect effects through altering hormone and cytokine levels Circulat-
ing adiponectin concentrations are inversely correlated with
fasting plasma insulin (Hotta et al, 2000), and adiponectin
stimulates the sensitivity of peripheral tissue to insulin (Yamamoto
et al, 2002). Several studies have supported an association of
Adiponectin and cancer
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elevated insulin production and/or insulin concentrations and
decreasing levels of IGFBP-3, with an increased risk of developing
several malignancies including colorectal and breast cancer (Kaaks
et al, 2000; Moschos et al, 2002). In obesity, reduced adiponectin
levels lead to the development of insulin resistance and com-
pensatory, chronic hyperinsulinaemia. Increased insulin levels, in
turn, lead to reduced liver synthesis and blood levels of insulin-like
growth factor binding protein 1 (IGFBP1) and IGFBP2, and
probably also reduce IGFBP1 synthesis locally in other tissues.
This results in increased levels of bioavailable IGF1. Insulin and
IGF1 signal through the insulin receptors (IRs) and IGF1 receptor
(IGF1R), to promote cellular proliferation and inhibit apoptosis in
many tissue types upregulating the secretion of vascular endothe-
lial growth factor, contributing thus to carcinogenesis (Calle and
Kaaks, 2004).
Adiponectin has also been shown to inhibit both the production
of TNF-a in macrophages and its action in endothelial cells (Ouchi
et al, 1999). Although generally considered proapoptotic, TNF-a
can also stimulate both oestrogens biosynthesis and angiogenesis
(Rose et al, 2004). Therefore, low adiponectin levels can potentially
lead to carcinogenesis through altered effect of TNF-a on tumour
cell proliferation. Further studies are needed to fully elucidate
these and potentially other molecular pathways.
Direct effects of adiponectin on carcinogenesis Adiponectin can
also protect from carcinogenesis through more direct effects.
Specifically, adiponectin has been found to be an important
negative regulator of hematopoiesis and the immune system
(Yokota et al, 2000). Yokota et al have shown that adiponectin
suppresses the growth of myelomonocyte cells lines in vitro,
induces apoptosis in myelomonocytic progenitor cells (leukaemia
lines), modulates expression of apoptosis-related genes in M1 cells
and downregulates Bcl-2 gene expression (Yokota et al, 2000).
Adiponectin selectively binds to several mitogenic growth
factors, such as PDGF-BB, basic FGF and HB EGF (Wang et al,
2005), that can induce proliferation in many types of cells. The
interaction of adiponectin with these growth factors can preclude
their binding to the membrane receptors suggesting that the
antiproliferative effect of adiponectin could at least in part be
due to its selective sequestration of growth factors at a prereceptor
level(Wang et al, 2005). Moreover, adiponectin may inhibit
activation of nuclear factor – kB (NF-kB), a transcription factor
that upregulates VEGF in breast cancer cells.
Signalling pathways linking adiponectin with carcinogenesis Sev-
eral signalling molecules such as 50-AMP-activated protein kinase
(AMPK), nuclear factor-kB (NF-kB), peroxisome proliferators-
activated receptor (PPAR)-a and p38 mitogen-activated protein
(MAP) kinase are known to mediate adiponectin-induced meta-
bolic effects. More recently, c-Jun NH2-terminal kinase (JNK) and
signal transducer and activator of transcription 3 (STAT3) were
also shown to be downstream effectors of adiponectin (Miyazaki
et al, 2005).
(a) AMPK, adiponectin, and their association with carcino-
genesis (Figures 1 and 2): The molecular pathways downstream of
AdipoR remain to be fully elucidated, but studies in metabolically
responsive cells have shown that activation of the pleiotropic
AMPK is part of the signalling cascade downstream of adiponectin
receptor (Goldstein and Scalia, 2004; Luo et al, 2005). AMPK is a
ubiquitously expressed abg heterotrimer consisting of a catalytic
subunit (a) and two noncatalytic subunits (b) (g). In addition to
exercise and starvation, AMPK is activated by the fat-cell-derived
hormones adiponectin and leptin (Yamauchi et al, 2002),
catecholamines (Kelly et al, 2004) and IL-6 (Kelly et al, 2004).
Once activated, AMPK exerts direct effects on specific enzymes
and transcriptional regulators, stimulating multiple events that
enhance ATP generation and inhibiting others that consume ATP
but are not acutely necessary for survival (Luo et al, 2005).
The enzymes downstream of AMPK include the mammalian
homologue of target of rapamycin (mTOR), acetyl-CoA carboxy-
lase (ACC), fatty acid synthase (FAS) and glycerol phosphate
acyltransferase (GPAT), which are key regulators of protein, fatty
acid and glycerolipid synthesis, respectively (Luo et al, 2005).
AMPK has been reported to inhibit FAS (Kuhajda, 2000; Luo
et al, 2005), a key lipogenic enzyme, which has been associated
with colon, breast, prostate and ovarian cancer (Kuhajda, 2000).
Finally, AMPK phosphorylates and activates TSC2, a tumour
suppressor that negatively regulates protein synthesis by inhibiting
mTOR. mTOR has been associated with colon, breast, prostate,
ovarian, liver and lung cancer (Philp et al, 2001). The regulation of
TSC2 and mTOR by AMPK might have special implications
because the PI3K-Akt signalling pathway is constitutively active in
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Figure 1 Multiple potential signalling pathways for adiponectin. Abbre-
viations: R1 and R2, adiponectin receptor type 1 and 2; AMP kinase,
adenosine 50-monophosphate (AMP)-activated protein kinase; NADPH,
nicotinamide adenine dinucleotide phosphate; oxLDL, oxidized low-density
lipoprotein; PI-3K, phosphatidylinositol-3-kinase; Akt, agarose kinase target
or protein kinase B; ROS, reactive oxygen species; NO, nitric oxide; eNOS,
endothelial NO synthase; MAPK, mitogen-activated-protein-kinase. The
solid arrows and dotted lines reflect stimulatory and inhibitory effects,
respectively. Modified from Goldstein and Scalia: JCEM, June 2004,
89(6):2565.
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Figure 2 Possible molecular mechanisms of regulation of tumour cell
growth by AMPK (12). Abbreviations: AMP kinase, adenosine 50-
monophosphate (AMP)-activated protein kinase; PI-3K, phosphatidylinosi-
tol-3-kinase; Akt, agarose kinase target or protein kinase B; mammalian
target of rapamycin (mTOR); fatty acid synthase (FAS). The solid arrows
and dotted lines reflect stimulatory and inhibitory effects, respectively.
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many cancers (Figure 2). The activation of this pathway is most
notable in cancers that have either inactivating mutations of the
PTEN gene (e.g. glioblastoma, melanoma, prostate cancer and
endometrial carcinomas) or overexpression of an activated
member of the epidermal growth factor (EGF) receptor family
(e.g. Her2/neu in breast cancer) (Luo et al, 2005).
Activation of AMPK by adiponectin also activates endothelial
NO synthase (eNOS) and increases nitric oxide (NO) production.
eNOS activation is also dependent on signalling through Akt
kinase (Akt) and its upstream mediator phosphatidylinositol
3-kinase (PI-3K) (Goldstein and Scalia, 2004). The exact role of
the adiponectin pathway in the inhibition of angiogenesis remains
to be fully elucidated. As AMPK may also stimulate angiogenesis
in vitro in response to hypoxia (Ouchi et al, 2005), whether an
antiangiogenic effect of adiponectin is mediated by AMPK or
eNOS-NO needs to be further investigated.
In summary, through these actions AMPK might reduce the risk
for developing cancers for which molecules such as mTOR may act
like mitogens (Luo et al, 2005) (Figure 2). As adiponectin
stimulates AMPK, (Goldstein and Scalia, 2004; Luo et al, 2005)
which might inhibit the growth and/or survival of cancer cells,
(Saitoh et al, 2004) the above molecular pathways may be potential
mechanisms through which adiponectin regulates carcinogenesis.
(b) Other mechanisms (independent of AMPK) linking adipo-
nectin with carcinogenesis: Adiponectin inhibits superoxide
production (ROS), possibly through inhibition of cellular NADPH
oxidase activity (Goldstein and Scalia, 2004). Reduced ROS
generation may increase NO production (by improvement of the
suppression of eNOS activity by ROS) and reduce cell proliferation
by blocking oxLDL induced mitogen-activated protein
kinase pathway (MAPK) activation (Goldstein and Scalia, 2004)
(Figure 1).
Finally, adiponectin may also regulate angiogenesis negatively
(independently of AMPK) through induction of apoptosis in
vascular endothelial cells by activating the caspase cascade, a
group of apoptotic enzymes. Adiponectin initially activates
caspase-8, which subsequently leads to activation of caspases-9
and -3, which in turn leads to cell death (Brakenhielm et al, 2004).
(c) JNK and STAT 3: a novel-signalling pathway linking
adiponectin with carcinogenesis (Figure 1): JNK belongs to the
mammalian mitogen-activated protein (MAP) kinase families, is
activated in response to various stimuli such as cytokines, and
mediates the phosphorylation and activation of transcription
factors such as c-Jun (Davis, 2000). In addition to its role in obesity
and insulin resistance, JNK is involved in the regulation of cell
proliferation and apoptosis during various physiological and
pathological events, including tumour development (Davis,
2000). The transcription factor STAT3 also regulates cellular
function such as cell proliferation, survival, differentiation and
apoptosis (Bowman et al, 2000). STAT3 is activated by adipokines
such as IL-6, leptin, which activate the Janus kinase-signal
transducer and activator of transcription (JAK-STAT) pathway.
Dysregulation of the STAT system directly contributes to
malignant transformation and cancer progression (Bowman
et al, 2000). It was recently demonstrated that adiponectin stimu-
lates JNK activation in prostate cancer (DU145, PC-3 and LNCaP-
FGC cells), hepatocellular carcinoma (HepG2) cells and C2C12
myoblasts, but also drastically suppresses STAT3 activation in
DU145 and HepG2 cells, in which STAT3 is constitutively activated
(Miyazaki et al, 2005). This suggests that adiponectin may affect
the pathogenesis of prostate and hepatocellular carcinomas, which
express AdipoR1 and R2 receptors, by acting on tumour cells
directly through modulation of JNK and STAT3 (Miyazaki et al,
2005). More studies are needed to further elucidate this area.
CONCLUSION
Adipose tissue is no longer considered an inert depot storage
organ but an active endocrine organ. Among the various proteins
released by adipocytes, adiponectin appears to play an important
role not only in glucose and lipid metabolism but also in the
development and progression of various types of cancers as well.
Low serum adiponectin levels may be a novel risk factor for cancer
and study of adiponectin biology can provide new insights into
the association of obesity with cancer risk. Since the mechanisms
of action of adiponectin are not entirely clear, future studies are
needed to fully elucidate the action of this hormone.
Accumulating evidence indicates that adiponectin measure-
ments may serve as a useful screening tool for predicting risk for,
and/or for early detection of obesity related cancers. Adiponectin
per se or adiponectin analogues may prove to be effective
anticancer agents and may have important therapeutic implica-
tions. In addition, methods to increase circulating adiponectin
levels including PPARg agonists or methods leading to upregula-
tion of adiponectin receptors and/or development of specific
adiponectin receptor agonists (e.g. osmotin) (Kadowaki and
Yamauchi, 2005), could prove beneficial in several obesity related
malignancies. In this regard, more intensive basic and clinical
research efforts are warranted.
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